Literature DB >> 8372438

Mutational analysis of hepatitis B virus enhancer 2.

S T Chen1, P La Porte, J K Yee.   

Abstract

Hepatitis B virus (HBV) infection is associated with the development of hepatocellular carcinoma in humans. HBV infection is primarily restricted to hepatocytes, and replication and gene expression of HBV require liver-specific transcription factors. Regulation of HBV gene expression has been shown to be controlled by two enhancers, and liver-specific gene expression of HBV can be attributed largely to the activity of enhancer 2. In this study, we have used mutational analysis to identify a 20-base-pair sequence motif essential for the liver-specific enhancer 2 activity. Analysis of the sequence reveals that this motif is similar to the regulatory region of several other liver-specific cellular genes, suggesting that common transcription factors may be involved in the activation of cellular as well as HBV gene expression in hepatocytes.

Entities:  

Mesh:

Year:  1993        PMID: 8372438     DOI: 10.1006/viro.1993.1521

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  4 in total

1.  Integrated hepatitis B virus DNA preserves the binding sequence of transcription factor Yin and Yang 1 at the virus-cell junction.

Authors:  M Nakanishi-Matsui; Y Hayashi; Y Kitamura; K Koike
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.

Authors:  K Ueda; Y Wei; D Ganem
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B.

Authors:  Wenmei Fan; Bingyi Shi; Hongshan Wei; Guosheng Du; Shujing Song
Journal:  Virus Genes       Date:  2010-12-16       Impact factor: 2.332

4.  The EIIAPA chimeric promoter for tumor specific gene therapy of hepatoma.

Authors:  Ya-Ju Hsieh; Fu-Du Chen; Chien-Chih Ke; Hsin-Ell Wang; Chih-Jen Huang; Ming-Feng Hou; Kang-Ping Lin; Juri G Gelovani; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.